TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04674956
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 antibody（Camrelizumab）, 200mg, D1; every 21 days as a cycle.
Study: NCT04674956
Drug: Paclitaxel(Albumin Bound) and Gemcitabine
Normalized name: Paclitaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel(Albumin Bound), 125 mg/m2D18; Gemcitabine, 1000mg/m2D1, 8;every 21 days as a cycle.
Study: NCT06312683
Drug: Rifaximin 550 MG Oral Tablet [XIFAXAN]
Normalized name: rifAXIMin 550 MG Oral Tablet [XIFAXAN]
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin 550 MG Oral Tablet \[XIFAXAN\] Taken twice a day for up to 365 days
Study: NCT05917340
Drug: High dose rifampicin (25mg/kg)
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given for 2 months
Study: NCT05917340
Drug: Moxifloxacin 400mg
Normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given for 2 months
Study: NCT05917340
Drug: Aspirin 150 mg
Normalized name: aspirin 150 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given for 2 months
Study: NCT05917340
Drug: Isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given for 6 months
Study: NCT05917340
Drug: Pyrazinamide
Normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given for 6 months
Study: NCT05917340
Drug: Rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard dose for 4 months after the initial treatment with high dose
Study: NCT05917340
Drug: HRZE
Normalized name: Isoniazid, Rifampicin, Pyrazinamide, Ethambutol
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 months
Study: NCT05917340
Drug: HRE
Normalized name: Threda
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7-10 months as per TB program guidelines
Study: NCT05107115
Drug: rilzabrutinib
Normalized name: Rilzabrutinib
DrugBank: Rilzabrutinib (DB17709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral use
Study: NCT05468229
Drug: Dorzagliatin
Normalized name: Dorzagliatin
DrugBank: Dorzagliatin (DB15123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose of dorzagliatin 50 mg
Study: NCT04843020
Drug: ION 682884
Normalized name: Potassium (ion)
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous injection every month
Study: NCT05560360
Drug: Efavirenz tablet
Normalized name: Efavirenz Tablets
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mg/tablet; administered orally
Study: NCT04479072
Drug: Aspirin 81 mg
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects in the interventional arm will receive a daily dose of aspirin 81 mg, starting at their baseline visit and to be taken up to their 6-month follow-up visit.
Study: NCT04882293
Drug: Atorvastatin 20 mg / Fenofibrate 160 mg in fixed dose
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet once a day, 20 mg /160 mg, Orally
Study: NCT04882293
Drug: Atorvastatin (Lipitor ®)
Normalized name: atorvastatin Oral Tablet [Lipitor]
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet once a day, 20 mg, Orally
Study: NCT04617171
Drug: Benralizumab 30 MG/ML [Fasenra]
Normalized name: benralizumab 30 MG/ML [Fasenra]
DrugBank: Benralizumab (DB12023)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Benralizumab/placebo initiated at an acute severe asthma exacerbation, then continued over a period of 48 weeks
Study: NCT05833815
Drug: Everolimus 10 mg
Normalized name: everolimus 10 MG
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral Everolimus 10 mg daily in addition to standard of care i.e. GemOx or CapOx
Study: NCT04825938
Drug: Toripalimab , Carboplatin, Nab-paclitaxel
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive toripalimab IV on day 1, paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT05313308
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam oromucosal solution
Study: NCT06064812
Drug: palbocilib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The palbociclib dose is the fixed approved dose: 125 mg intake daily, for consecutive 21 days then off for 7 days, which composes 28-day treatment cycle, which is consistent with the 28-day treatment cycle of FWD1802.~Every treatment cycle consists of 28 days.
Study: NCT04757090
Drug: 89Zr-trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: -To minimize uptake of the 89Zr-trastuzumab in normal tissues, immediately prior to planned 89Zr-trastuzumab injection patients will receive a 50 mg dose of cold unlabeled trastuzumab intravenously (IV). The administration of a fixed small dose of unlabeled antibody to improve tumor-to-normal-tissue (T/N) uptake of the radiolabeled antibody is standard in this type of imaging procedure.
Study: NCT05166876
Drug: Brequinar Sodium
DrugBank: Brequinar (DB03523)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg, 100 mg, 150 mg, 200 mg x 5 days
Study: NCT05166876
Drug: Dipyridamole 75 MG
Normalized name: dipyridamole 75 MG
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg TID for 5 days
Study: NCT06224257
Drug: Linperlisib
Normalized name: Linperlisib
DrugBank: Linperlisib (DB17235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated PI3K activity in T-LGL likely plays an important role in the ability of the pathologic cells to avoid homeostatic apoptosis, since inhibition of this pathway leads to apoptosis in the population of cells harboring the pathologic clone. More importantly, the activity of this pathway may represent a kind of Achilles heel for T-LGL in that PI3K inhibitors alone are quite effective at inducing spontaneous apoptosis in the clonal CTLs after a short incubation.
Study: NCT06191640
Drug: Ivacaftor or elexacaftor/tezacaftor/ivacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: HEMT's are prescribed at the discretion of the treating physician and is not dictated by the principal investigator of this study.
Study: NCT00051597
Drug: SGN-30 (monoclonal antibody)
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: SGN-30 (DB05471)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05232175
Drug: ALT-BB4
Normalized name: ALT-801
DrugBank: ALT-801 (DB15386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Hyaluronidase
Study: NCT05232175
Drug: 0.9%NaCl
Normalized name: triamcinolone acet/0.9%NaCl/PF 40 mg/mL INJECTION VIAL (ML)
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal Saline
Study: NCT05755438
Drug: Ruxolitinib Cream
Normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib cream 1.5% twice daily (BID) during the vehicle controlled (DBVC)and open label treatment period (OLE).
Study: NCT05607615
Drug: Hydroxypropyl Beta Cyclodextrin
Normalized name: Hydroxypropyl beta cyclodextrin
DrugBank: Hydroxypropyl betadex (DB15379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimum active dose of 500 mg/kg (equivalent to 18,500 mg/m2) as an intravenous (IV) infusion once every 28 days
Study: NCT05576896
Drug: Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab
Normalized name: Thiazides, combinations with psycholeptics and/or analgesics
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prior to starting therapy, patients will have a pretreatment cross-sectional scan. Patients will then begin with encorafenib 300 mg daily starting with Cycle 1 day 1; then patients will receive IV cetuximab weekly, with 400 mg/m2 on C1D1 as a loading dose and 250 mg/m2 on all other days.~Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Study: NCT04840004
Drug: PVT-1
Normalized name: Pivalic Acid
DrugBank: Pantothenyl-Aminoethanol-Acetate Pivalic Acid (DB03045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Since there is no specific dose range is available for testing the anti-tumor effects of PVT-1 in clinical trials settings, in the present study the dose of PVT-1 will be up-titrated 250/160/160 mg to maximum 1000/640/640 mg as described in study methodology section.
Study: NCT05013801
Drug: 2% Hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2% Hydroquinone cream
Study: NCT05909644
Drug: Omaveloxolone
Normalized name: Omaveloxolone
DrugBank: Omaveloxolone (DB12513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omaveloxolone Capsules, 150 mg, administered orally
Study: NCT05909644
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz Tablet, 600 mg, administered orally once daily
Study: NCT05093634
Drug: Setmelanotide
Normalized name: Setmelanotide
DrugBank: Setmelanotide (DB11700)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous Injection
Study: NCT05817643
Drug: BMS-984923
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral capsule
Study: NCT04123314
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing at the first session will be 15 mg/70 kg. For the second session participants will either remain at the initial dose, or increase to 25 mg/70 kg at the discretion of the study team.
Study: NCT05938517
Drug: Betahistine dihydrochloride
Normalized name: Betahistine Dihydrochloride
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject received single dosages of Betahistine (24 mg, 48 mg, 96 mg) for pharmacokinetic serum draw with at least two days between the different dosages.
Study: NCT05938517
Drug: Selegiline-hydrochloride
Normalized name: Selegiline Hydrochloride
DrugBank: Selegiline (DB01037)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the second period, each subject was pre-treated with Selegiline (5 mg/day) for one week and treated continuously with Selegiline (5 mg/day) in combination with the single dosages of Betahistine (24 mg, 48 mg, 96 mg) with at least two days between the different dosages.
Study: NCT06105632
Drug: PF-07220060 CDK4 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental
Study: NCT06105632
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Experimental and Active comparator
Study: NCT06105632
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Active Comparator
Study: NCT06105632
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active Comparator
Study: NCT06271837
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan by intravenous infusion
Study: NCT06271837
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab by intravenous infusion
Study: NCT06559150
Drug: Nebulized Ensifentrine Suspension; 3 mg
DrugBank: Ensifentrine (DB16157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by a standard jet nebulizer, twice daily for a minimum of 24 weeks and up to a maximum of 156 weeks (3 years)
Study: NCT00000880
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04167813
Drug: Ondansetron 8mg or matched placebo tablets
Normalized name: ondansetron 8 MG
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will take one tablet daily in weeks 1 and 2, two tablets daily in weeks 3 and 4 and 3 tablets daily in weeks 5 and 6.~Dose escalation will be guided by tolerability, through telephone safety monitoring prior to each dose increase
Study: NCT06169124
Drug: Darolutamide
Normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT06169124
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT06169124
Drug: Leuprolide Acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IM
Study: NCT04475991
Drug: Maraviroc + Currently used therapy
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc tablets. 300 mg bid, given orally for a 10 day period AND CT (Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga)
Study: NCT04475991
Drug: Favipiravir + Currently used therapy
Normalized name: Monistat Simple Therapy
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Favipiravir tablets 200 mg. given orally for a 7 day period. 1600 mg bid on day 1 and 600 mg tid days 2-7 AND CT (Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga).
Study: NCT04475991
Drug: Maraviroc+Favipiravir+CT
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc tablets. 300 mg bid, given orally for a 10 day period AND Favipiravir tablets 200 mg. given orally for the first 7 days. 1600 mg bid on day 1 and 600 mg tid days 2-7 AND CT (Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga)
Study: NCT04206059
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All participants will receive dexmedetomidine with sedation titrated step-wise to 2, 3 or 4 ng/ml
Study: NCT06256536
Drug: GZR18
Normalized name: Grazoprevir
DrugBank: Grazoprevir (DB11575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.6 mg-30 mg
Study: NCT05184049
Drug: Epalrestat,Mecobalamin
DrugBank: Mecobalamin (DB03614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epalrestat will be taken orally at a dose of 50mg 3 times a day before meals. In addition, conventional hypoglycemic and oral mecobalamin treatment 0.5mg/ time, 3 times/day, before meals.
Study: NCT05184049
Drug: Mecobalamin
Normalized name: Mecobalamin
DrugBank: Mecobalamin (DB03614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects takes mecobalamin 0.5mg orally, 3 times a day.Regular hypoglycemia.
Study: NCT05116215
Drug: Hydrogen
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogen supplement
Study: NCT06281834
Drug: Rifapentine
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Children 2-11 years received standard HIV treatment and 3HP (RPT/INH weekly for 12 weeks) for TB prevention. Children \<2 years receive standard HIV treatment, a single-dose of extrapolated weekly RPT/INH, followed by standard INH prophylaxis. Safety and pharmacokinetics will be evaluated.
Study: NCT06281834
Drug: Dolutegravir
Normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All children in this study are living with HIV and thus dolutegravir is a standard part of treatment; in this study we will collect blood samples to measure dolutegravir levels during combination treatment with rifapentine/isoniazid treatment for TB prevention
Study: NCT04937062
Drug: Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]
Normalized name: glycerol phenylbutyrate 1100 MG/ML [Ravicti]
DrugBank: Glycerol phenylbutyrate (DB08909)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Glycerol phenylbutyrate (trade name Ravicti) is an FDA-approved medication used for urea cycle disorders in children and adults. We will titrate to a goal dose of 1.2 mL/m2 (12.4 g/m2) in three equally divided doses given enterally (i.e., by mouth or by g-tube).~The dosing is consistent with the dosing guidelines in the FDA approved Medication Guide (https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203284s005lbl.pdf).
Study: NCT04981899
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 6 infusions of nivolumab at a fixed dose of 40 mg, 14 days apart, and infusion of nivolumab on day 0 of the NICE-40.
Study: NCT04981899
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5000 mg / m2, 24-hour infusion on day 2 of the NICE-40.
Study: NCT04981899
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Optimized to get AUC = 5 (max. 800 mg) on day 2 of the NICE-40.
Study: NCT04981899
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg / m2 intravenously on 1-3 days of the NICE-40.
Study: NCT06442280
Drug: Dapagliflozin tablet
Normalized name: Dapagliflozin Tablets
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 10 mg 1 tablet once daily
Study: NCT06442280
Drug: Furosemide Injection
Normalized name: furosemide Injection
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide 20 mg
Study: NCT04719000
Drug: rhFSH+rhLH
Normalized name: rhTSH
DrugBank: Thyrotropin alfa (DB00024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 IU of rhFSH and 150 IU of rhLH (Pergoveris®) GnRH antagonist: cetrorelix 0.25 mg (Cetrotide® - Merck) GnRH antagonist: cetrorelix 0.25 mg (Cetrotide® - Merck) Recombinant human chorionic gonadotropin (rhCG) 6500 IU (Ovitrelle® - Merck) micronized progesterone 90 mg (Crinone 8% ® - Merck)
Study: NCT04719000
Drug: rhFSH
Normalized name: rhTSH
DrugBank: Thyrotropin alfa (DB00024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 IU rhFSH (Gonal-F®- Merck) GnRH antagonist: cetrorelix 0.25 mg (Cetrotide® - Merck) GnRH antagonist: cetrorelix 0.25 mg (Cetrotide® - Merck) rhCG 6500 IU (Ovitrelle® - Merck) micronized progesterone 90 mg (Crinone 8% ® - Merck)
Study: NCT06224400
Drug: ENC1018 for SAD
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (cohort A1-A6) to receive either ENC1018 or placebo. The investigational product (ENC1018 or placebo) will be administered orally as a single dose.
Study: NCT05456269
Drug: Bisantrene Dihydrochloride (high dose)
Normalized name: Levocetirizine Dihydrochloride
DrugBank: Bisantrene (DB17247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction monotherapy cycle: IV bisantrene daily on Days 1 to 7, starting at 250 mg/m2 then adjusted to either 275 mg/m2 or 225 mg/m2 based on confirmed dose (Run-in) Consolidation combination cycle/s: IV bisantrene daily on Days 1 to 2
Study: NCT05456269
Drug: Bisantrene Dihydrochloride (low dose)
Normalized name: ethinyl estradiol
DrugBank: Bisantrene (DB17247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV bisantrene at escalating doses for 3 dose levels of 50, 65, 85 mg/m2 on Days 3 and 5 until Maximum tolerated dose (MTD) reached.
Study: NCT05456269
Drug: Cytarabine Hydrochloride
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Consolidation cycles: continuous IV cytarabine (100mg/m2) on Days 1 to 5
Study: NCT00386659
Drug: tenofovir + abacavir + lopinavir/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00386659
Drug: tenofovir + abacavir + efavirenz
Normalized name: efavirenz / lamivudine / tenofovir disoproxil
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05700864
Drug: Cenegermin-Bkbj
Normalized name: cenegermin-bkbj
DrugBank: Cenegermin (DB13926)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Cenegermin-bkbj ophthalmic solution administered as one drop in both eyes every 3 hours 4 times daily for 4 weeks
Study: NCT06440902
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab is given In patients with NeoRAS WT
Study: NCT04884893
Drug: Nitrous Oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50% nitrous oxide
Study: NCT05612711
Drug: Dronabinol
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will take both dronabinol and placebo at different points in the study in this crossover design trial.
Study: NCT05269849
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus (1, 2, or 5 mg tablets) given for 3 months followed by a washout period of 3 months
Study: NCT05253846
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: chemotherapy treatment
Study: NCT05253846
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: chemotherapy treatment
Study: NCT05253846
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: chemotherapy treatment
Study: NCT04098250
Drug: Erenumab
Normalized name: ERENUMAB
DrugBank: Erenumab (DB14039)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: a CGRP receptor monoclonal antibody
Study: NCT04879628
Drug: SAR441344 IV
Normalized name: Immunoglobulin G1 (272-arginine,325-alanine), anti-(human CD40 ligand) (human-mus musculus monoclonal SAR441344 gamma1-chain), disulfide with human-mus musculus monoclonal SAR441344 kappa-chain, dimer
DrugBank: Frexalimab (DB18926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution Route of administration: IV infusion
Study: NCT04879628
Drug: SAR441344 SC
Normalized name: Immunoglobulin G1 (272-arginine,325-alanine), anti-(human CD40 ligand) (human-mus musculus monoclonal SAR441344 gamma1-chain), disulfide with human-mus musculus monoclonal SAR441344 kappa-chain, dimer
DrugBank: Frexalimab (DB18926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution Route of administration: SC injection